Ocular surface and epithelial cell lipid membranes

The ocular surface and epithelial cell lipid membranes represent a complex physiological system essential for maintaining the health and optical clarity of the eye. This target encompasses the lipid layer of the tear film, primarily secreted by the Meibomian glands, and the plasma membranes of the corneal and conjunctival epithelial cells. The primary biological function of these lipid structures is to provide a hydrophobic barrier that prevents the evaporation of the underlying aqueous tear layer and protects the underlying tissue from environmental insults and pathogens (TFOS DEWS II, 2017). In diseases such as Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD), the integrity of these membranes is compromised, leading to tear film instability, increased osmolarity, and subsequent inflammation and epithelial damage (PubMed: 28552559). Pharmacological intervention targeting these membranes often involves the use of lubricants, surfactants, or semi-fluorinated alkanes. For example, perfluorohexyloctane (Miebo) is a recently approved drug that specifically targets the tear film lipid layer by forming a monolayer at the air-tear interface, thereby reducing evaporation and stabilizing the ocular surface (FDA, 2023). Other treatments, such as phospholipid-based eye drops, aim to supplement the natural lipid composition of the tear film or stabilize the epithelial cell membranes to enhance the ocular barrier and alleviate symptoms of dryness and irritation.

Other names

Tear film lipid layerOcular surface barrierCorneal epithelial cell membranesConjunctival epithelial cell membranesPre-corneal lipid film

Therapeutic agents interact with these membranes by forming a protective surfactant layer, supplementing the natural lipid film to reduce evaporation, or stabilizing the epithelial cell bilayer to prevent desiccation and mechanical damage.